A Phase 1 interventional study of CoFactor and Leucovorin in Healthy Adults, sponsored by Mast Therapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2009-05-28.
Sponsored by Mast Therapeutics, Inc. · Phase 1, Interventional, and Treatment
The purpose of this study is to determine the safety and tolerability of CoFactor in healthy subjects.
Mast Therapeutics, Inc. is the lead sponsor of 14 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
CoFactor
Drug: CoFactor
CoFactor
Drug: CoFactor
Leucovorin
Drug: Leucovorin
Also known as: ANX-510
Pharmacokinetic profile of CoFactor formulations in healthy adult subjects.
To measure the 5,10 methylenetetrahydrofolic acid levels after CoFactor and leucovorin administration
This study is completed, as verified in May 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Mast Therapeutics, Inc.